Plasmid DNA Manufacturing Market to Reach Valuation US$ 300 Mn by 2026

LOS ANGELES, March 11, 2020 /PRNewswire/ -- The global plasmid DNA manufacturing market is expected to reach valuation over US$ 300 million by 2026.

https://mma.prnewswire.com/media/962993/Acumen_Research_and_Consulting_Logo.jpg

Acumen Research & Consulting, a global provider of market research studies, in a recently published report titled "Plasmid DNA Manufacturing Market (By Application: Gene Therapy, Vaccinology; By Disease: Infectious Disease, Cancer, Genetic Disorder: Research Institute , Biotech Companies; By Region: North America, Europe, Asia Pacific, Latin America, Middle East & Africa) - Global Industry Size, Share, Trends and Forecast 2019 - 2026".

Get Free Report Sample Pages for Better Understanding@ https://www.acumenresearchandconsulting.com/request-sample/1583

During the forecast period, the growing growth of the gene therapy market is likely to be seen in demand by plasmid DNA contract manufacturers. In addition, in recent years the demand for cell and gene therapy has increased substantially. According to recent findings from the Alliance of Regenerative Medicine (ARM), the funding of different cell and gene therapies was increased by over 75% year-on-year. Cell and gene therapies have taken place in a league of over 2,600 clinical trials reported to date. The growing demand for these therapies has given vector manufacturers new opportunities.

As a result of strategies such as market players working together, in Europe are expected to see significant growth in the plasmid DNA manufacturing market. For instance, in May 2018, Plasmid Factory GmbH & Co. KG has partnered with Vibalogics GmbH, Sirion-Biotech GmbH, and PROGEN for the development of vector adeno-associated virus (AAV). The goal of this collabration was to make the development of plasmid products simple and the study of recombinant AAVs to meet customers' requirements.

Advancing Plasmid Manufacturing at Aldevron

    --  Aldevron has developed plasmid DNA in 1998. They initially supplied
        research material and then extended to custom plasmid DNA for clinical,
        preclinical, and commercial purposes.
    --  The plasmids needed for viral vectors (AAV, lentivirus), DNA, CAR-T cell
        therapy, gene editing, cloning, DNA vaccines, personalised cell therapy
        and other applications have proved their expertise in Aldevron.
        Companies that seek novel products, including Sarepta for Duchenne's
        gene therapy and Genprex's lung cancer plasmid DNA, turn to Aldevron to
        be their plasma DNA suppliers.
    --  It can generate supercoiled, circular, minicroplasma, nanoplasmid and
        bacmid-plasma DNA and is capable of producing hundreds of grams per lot
        and hundreds of thousands of large-scale plasmid prepares per day. They
        will supply plasmid DNA in scientific, industrial and research
        applications.
    --  To meet different customer requirements, Aldevron manufactures plasmids
        at different service levels. For high-quality plasmid DNA, the research
        class is the fastest option. A cost-effective alternative to cGMP is
        GMP-SourceTM. Their cGMP service provides oversight and process
        management of highest quality and can support any demand, including
        parenteral administration.
    --  Aldevron also recently began supplying bulk off-shelf plasmids for AAV
        and lentiviral vector production. The immediate availability and costs
        for the manufacture of AAV and LV vectors are significantly reduced by
        the immediate use of these plasmids and also risk reduction is
        simplified by a reliable manufacturer of consistent high quality
        products. The plasmids inventory is also available at the level of
        research, GMP-SourceTM and cGMP.

Browse More Related Reports, Click Here@ https://www.acumenresearchandconsulting.com/industry-categories/healthcare-and-pharmaceuticals

Key market players depend on approaches like mergers and acquisitions to boost their product portfolio. For instance, in 2016, the exclusive collaboration for Agilis experimental gene therapy drug AGIL-FA for the treatment of Friedreich's ataxia (FA) was entered into Agilis Biotherapeutics, LLC (AGILis) and Waisman Bia Manufacturing. Similarly, the Aldevron Antibody Development Platform in Germany revealed an expansion plan in March 2019. This proposal has increased the development and laboratory space of the current facility to approximately 4300 square feet.

The guidelines also consider specific organizational structures and compliance skills for early phase studies:

    --  Large companies in pharmaceutical/biotechnology that are likely to
        supply products in the market
    --  Start-up companies that grow and transition products to phase 1-2 and
        then to larger organizations or partners
    --  Limited trials for scientific publications by universities and funding
        agencies

Key Insights

    --  The North America Plasmid DNA Manufacturing market size was over 26
        million USD in 2018 and is expected to witness the growth at a CAGR of
        around 22% from 2019 to 2026.
    --  The market in Asia Pacific is expected to witness faster growth, owing
        to factors such as increasing government expenditure on healthcare
        sector in order to facilitate R&D activities.
    --  The cancer market is expected to witness significant growth over the
        forecast period.

Market Segmentation

Market By Application

    --  Gene Therapy
    --  Vaccinology

Market By Disease

    --  Infectious Disease
    --  Cancer
    --  Genetic Disorder

Market By End use

    --  Research Institute
    --  Biotech Companies

Market By Region

    --  North America
    --  Europe
    --  Asia Pacific
    --  Latin America
    --  Middle East & Africa

Request for Customization@ https://www.acumenresearchandconsulting.com/request-customization/1583

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this premium research report@ https://www.acumenresearchandconsulting.com/buy-now/0/1583

If you would like to place an order or have any questions, please feel free to contact at sales@acumenresearchandconsulting.com | +1-407-915-4157 OR +1-408-900-9135

About Us

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. Among the industries served include aerospace and defense, information and communication technology (ICT), semiconductor and electronics, healthcare and pharmaceuticals, chemicals, advanced materials, banking, finance services and insurance (BFSI), and others.

Our collective industry experience of over 100 years has helped us to offer appropriate market information and our global reach and regional connects ensures appropriate insights into regional markets to guarantee apt delivery of information.

Our regional market intelligence helps our clients to identify potential opportunities and develop growth strategies across regions and countries. Our services are geared towards offering best market research to our clients.

Contact Us:
Mr. Frank Wilson
Acumen Research and Consulting
17890, Castleton St #218, Rowland Heights, CA 91748 United States
Tel: +1-407-915-4157 OR +1-408-900-9135
Email: sales@acumenresearchandconsulting.com
Website: https://www.acumenresearchandconsulting.com

View original content:http://www.prnewswire.com/news-releases/plasmid-dna-manufacturing-market-to-reach-valuation-us-300-mn-by-2026-301021439.html

SOURCE Acumen Research and Consulting